Fulgent Genetics Reports Second Quarter 2022 Financial Results

TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its second quarter ended June 30, 2022. Second Quarter 2022 Results:...

Click to view original post